Abstract: A resin composition containing a compound including phosphorus and sulfur as constituent elements and having a disulfide bond, and a thermoplastic resin.

Abstract: A compound comprising phosphorus atoms and sulfur atoms as constituent elements and having a peak in Raman spectroscopy, the peak being attributable to a disulfide bond bonding between two phosphorus atoms.

Abstract: The present invention pertains to a silkworm-type biotinylated CTLD14 or sRAGE and a method for manufacturing the same. One embodiment of the present invention provides a method for manufacturing biotinylated proteins, wherein the method includes A) a step for inserting a nucleic acid molecule for coding biotin ligase and protein in a coexpressable manner into a silkworm or a living organism that imparts sugar chains that are the same as the sugar chains of the silkworm, B) a step for causing the biotin ligase and protein to be expressed by disposing the silkworm or the living organism that imparts sugar chains that are the same as the sugar chains of the silkworm to conditions with which the nucleic acid molecule will carry out expression, and C) a step for administering biotin to the living organism and obtaining the biotinylated protein.

Abstract: Provided is a method for producing an electrode active material capable of forming a non-aqueous secondary battery with superior durability and output characteristics. The method for producing an electrode active material for a non-aqueous secondary battery includes contacting a dispersion containing graphene and a dispersion medium with alkali-metal-transition-metal composite oxide particles, and the dispersion has a dispersibility index of 0.25 or more.

Abstract: Provided is a method for producing an electrode active material capable of forming a non-aqueous secondary battery with superior durability and output characteristics. The method for producing an electrode active material for a non-aqueous secondary battery includes contacting a carbon material containing at least one selected from the group consisting of graphene, a carbon nanotube and carbon black with a one-electron oxidant having an oxidation-reduction potential of 0.2 V or more and 1.9 V or less to obtain at least one modified carbon material, and contacting the at least one modified carbon material with alkali-metal-transition-metal composite oxide particles.

Abstract: General Formula (I) Provided is an all solid state secondary-battery additive comprising a polyalkylene carbonate (I) represented by general formula (I), and by providing such additive, properties such as the charge-discharge capacity and interfacial resistance of an all-solid-state secondary battery are improved. (In general formula (I), R1 and R2 are each a C1-10 chain-like alkylene group or C3-10 cycloalkylene group, m is 0, 1, or 2 and n is an integer of 10 to 15000, and each R1, R2 and m in the polyalkylene carbonate (I) chain is independently the same or different.

Abstract: General Formula (I) Provided is an all solid state secondary-battery additive comprising a polyalkylene carbonate (I) represented by general formula (I), and by providing such additive, properties such as the charge-discharge capacity and interfacial resistance of an all-solid-state secondary battery are improved. (In general formula (I), R1 and R2 are each a C1-10 chain-like alkylene group or C3-10 cycloalkylene group, m is 0, 1, or 2 and n is an integer of 10 to 15000, and each R1, R2 and m in the polyalkylene carbonate (I) chain is independently the same or different.

Abstract: The present invention pertains to a silkworm-type biotinylated CTLD14 or sRAGE and a method for manufacturing the same. One embodiment of the present invention provides a method for manufacturing biotinylated proteins, wherein the method includes A) a step for inserting a nucleic acid molecule for coding biotin ligase and protein in a coexpressable manner into a silkworm or a living organism that imparts sugar chains that are the same as the sugar chains of the silkworm, B) a step for causing the biotin ligase and protein to be expressed by disposing the silkworm or the living organism that imparts sugar chains that are the same as the sugar chains of the silkworm to conditions with which the nucleic acid molecule will carry out expression, and C) a step for administering biotin to the living organism and obtaining the biotinylated protein.

Abstract: The present invention provides a metal paste composition which can obtain the calcined bodies having low volume resistivity in a wiring substrate after calcining. More specifically, the present invention provides a metal paste composition comprising a metal, an aliphatic polycarbonate, and an organic solvent.

Abstract: The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

Abstract: Pharmaceutical agents characterized by containing benzophenone derivatives represented by the general formula: wherein the each substituent is as defined in the specification, or salts thereof have suppressive effect on RANKL production, suppressive effect on OPG reduction and inhibitory effects on differentiation/activation of osteoclasts, and are extremely useful for treating, for example therapy and/or prevention, of various diseases in which differentiation/activation of osteoclast are involved, such as osteoporosis.

Abstract: Metal nanoparticles having improved migration resistance are provided. The present invention relates to a method for manufacturing composite nanoparticles including obtaining composite nanoparticles containing at least silver and copper in a single particle by heat treating a mixture containing an organic silver compound and an organic copper compound at a temperature of 150° C. or more in a non-oxidative atmosphere in the presence of a tertiary amine compound represented by the general formula R1R2R3N (wherein R1 through R3 are optionally substituted alkyl groups or aryl groups that may be the same or different, R1 through R3 may be linked in a ring, and the number of carbon atoms in each of R1 through R3 is 5 through 18 and may be the same or different).

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: Copper-containing nanoparticles with excellent oxidation resistance is provided. The present invention relates to a method for manufacturing copper-containing nanoparticles including obtaining copper-containing nanoparticles that contain an organic component by heat treating an organic copper compound at a temperature equal to or higher than a decomposition initiation temperature of the compound and lower than a complete decomposition temperature of the compound in a non-oxidative atmosphere in the presence of an organic material containing a 1,2-alkanediol having 5 or more carbon atoms and/or a derivative thereof.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: The present invention provides a metal paste composition which can obtain the calcined bodies having low volume resistivity in a wiring substrate after calcining. More specifically, the present invention provides a metal paste composition comprising a metal, an aliphatic polycarbonate, and an organic solvent.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.